Hope Sterling: Michael, okay — I have been vibrating about this since Tuesday, like genuinely could not stop sending people links.
Michael C. Vincent: I could tell. You sent me three links at midnight.
Hope Sterling: Because — okay, JAMA, July 8th, 2026 — Northwestern Medicine drops a study and the number is one hundred percent. Every single transplant patient alive past year one. Not ninety percent, not like ninety-five with a couple of asterisks — a hundred. And these are people who were told there is literally nothing left to do for them.
Michael C. Vincent: Hold on — stage IV lung cancer patients.
Hope Sterling: Stage IV non-small cell lung cancer, yes! And Dr. Ankit Bharat at the Canning Thoracic Institute just — he took out the diseased lungs and put in new ones. Like, that's it. That's the move. And Jodi Graf is alive right now because of it, she's in the national coverage, she is the proof. Northwestern is the only U.S. health system doing this, and I think — I genuinely think — this is the cure oncology forgot to try.
Michael C. Vincent: You see, that last line is the one I want to pull on. Because it's not wrong — but it's not the whole picture either.
Hope Sterling: No, I know, I know — but let me be loud about it first, because the number earns it.
Michael C. Vincent: Fair enough. Go.
Hope Sterling: Okay but — the number earns the loud take, right? Like I stand by that.
Michael C. Vincent: It earns attention. What it doesn't earn yet is the word cure. And here's where I want to slow down — because the ban on transplanting cancer patients wasn't arbitrary. It wasn't a bureaucratic quirk. Think of it like a house rule so old nobody remembers who made it: don't put the dog on the couch. You follow it, you don't question it. The rule was — active cancer is an absolute contraindication to lung transplantation. Categorical. And the logic was sound: the drugs you take after any transplant to stop your body rejecting the new organ? They suppress your immune system. And your immune system is also what hunts cancer cells. So you give someone new lungs, they go on immunosuppression, and whatever cancer remained — it has no predator left. You've handed it the keys.
Hope Sterling: Oh — oh, that's the thing I didn't fully get. It's not that cancer patients are too sick for surgery, it's that the medicine you have to take after surgery actively makes cancer worse.
Michael C. Vincent: That's the core of it. One clean sentence: the cure and the cancer use the same battlefield. Now — what Northwestern did, what Dr. Ankit Bharat did, wasn't smash that rule. They reread it. The rule assumes cancer is somewhere in the body. What if it's only in the lungs? Then you remove the lungs, you remove the cancer entirely. There's nothing left for the immunosuppression to empower.
Hope Sterling: Wait — so it's not even oncology logic, it's like, carpentry logic. The rot is only in that one board, so you replace the board.
Michael C. Vincent: You see, that's actually a better analogy than most journal editorials managed. And the DREAM registry — formally, NCT05671887, Double Lung Transplant Registry for Lung-Limited Malignancies — that's the structure they built around exactly that sentence. The eligibility is narrow, deliberately so: stage IV non-small cell lung cancer, confined entirely to the lungs, no extrapulmonary metastases, and every standard option — chemotherapy, radiation, immunotherapy, surgery — already exhausted. Lung-limited, medically refractory. Both conditions have to be true.
Hope Sterling: So it's not like, any cancer patient can walk in and get new lungs — this is like, the narrowest possible slice of people where the reread even holds.
Michael C. Vincent: Exactly narrow. And — I mean, this is the part worth pausing on — JAMA didn't just publish the study on July 8th. They published a simultaneous editorial by Ece Cali Daylan and Ramaswamy Govindan alongside it. The journal wanted a second opinion in the same issue. That's the scientific equivalent of saying: we believe this data, and we still want someone else in the room.
Hope Sterling: That detail — the journal commissioning its own skeptic in real time — that's actually kind of wild? Like even JAMA had a 'wait, really?' moment.
Michael C. Vincent: And that second opinion is where the story gets genuinely complicated. Because Daylan and Govindan didn't just say 'nice work.' They flagged the thing that won't leave the room — the 81 patients on standard medical management weren't a random control group. They were the people who couldn't qualify for transplant. Which means — and this matters — they were likely already sicker.
Hope Sterling: Wait — so we're not comparing like, same-stage patients who just got different treatment?
Michael C. Vincent: That's exactly the unanswered question. The DREAM registry selected for lung-limited, medically refractory patients stable enough to survive a double transplant. The 81 in the comparison group? They didn't clear that bar. You're measuring the healthiest cancer patients against everyone else. That's not a flaw in the study, necessarily — it's just what the data is.
Hope Sterling: Okay but — I mean, that's the part I keep going back and forth on, because — like, even granting that, even if the comparison group was sicker, a hundred percent still means Jodi Graf is alive. That's not a statistical artifact. That's a person breathing.
Michael C. Vincent: That's the kernel. That's where the loud take actually earns it.
Hope Sterling: Right — but the part that doesn't fit is what comes after year one. Like, the immunosuppression she's on forever to keep those donor lungs — those same drugs are telling her immune system to stand down. And if even one cancer cell survived the swap, it now has no predator. That's — that's not a solved problem, that's a loaded question they handed her to carry home.
Michael C. Vincent: No long-term disease-free survival data yet. That's the actual edge of the map.
Hope Sterling: Which is — okay, that's what scares me. And there's a whole other layer to this that is genuinely the hardest part of the whole story, and we're going to get there — the organ scarcity question, who doesn't get a lung if this scales — but that one I cannot even start on yet because my brain will explode.
Michael C. Vincent: Good. Hold that thought. Because the surgical logic is real, the hundred percent is real, and the selection bias is real — all three at once. That's where the honest version of this lives.
Hope Sterling: Okay but the scarcity thing — I cannot soft-pedal this anymore. Donor lungs are scarce. Like, genuinely, terrifyingly scarce. And if cancer patients enter the waitlist, they are competing directly against people with pulmonary fibrosis, COPD — people whose post-transplant outcomes are, like, way more established than a seventeen-person registry.
Michael C. Vincent: That's precisely what the Daylan and Govindan editorial puts on the table. Formally. In JAMA. The organ allocation fairness question isn't a blog post concern — it's the published scientific response.
Hope Sterling: Which means — wait, that means someone is already not getting a lung because Jodi Graf got one. That's not hypothetical. That's the math right now.
Michael C. Vincent: And the uncomfortable part is that we don't have long-term data to justify that trade yet. The DREAM registry tracks biomarkers alongside survival — which is real, careful science — but the three-to-five year immunosuppression window hasn't closed. If recurrence becomes the dominant story at year four, the whole allocation calculus inverts.
Hope Sterling: Stop — so we might be giving lungs to cancer patients, ahead of fibrosis patients, based on a one-year number that could fall apart by year five?
Michael C. Vincent: That's the live question. And the reproducibility problem sits right next to it — Northwestern is the only U.S. center offering this. Is that because Dr. Bharat's team has genuinely singular surgical expertise, or because no one else has tried? Those are very different answers with very different implications.
Hope Sterling: I mean — if it only works in Bharat's hands, that's not a paradigm shift, that's a talent.
Michael C. Vincent: That's the honest frame. The JAMA publication has opened a genuinely new clinical question. It has not answered whether the answer is yes at scale.
Hope Sterling: So the calibrated take is — this is real, it is new, Jodi Graf is breathing, and we still owe the people on the fibrosis waitlist a conversation that one registry cannot have for us.
Michael C. Vincent: Northwestern published in JAMA on July 8th, 2026. The DREAM registry is the only program of its kind in the United States. And the immunosuppression clock is ticking from the moment those new lungs go in. We'll know in three to five years whether this was a breakthrough or a beautiful first chapter with a bad ending.
Hope Sterling: Okay — I mean, 'cure' was probably a stretch. I'll give you that. But 'remove the problem organ entirely and see what happens' is still — like, that is the most audacious reframe in oncology this decade, and I sent you those links at midnight because that is worth losing sleep over.
Michael C. Vincent: You sent three. That detail holds up.
Hope Sterling: Three was the right number.
